Commonly Used Brand Names of Valproic Acid
The most commonly used brand names of valproic acid in the market are Depakene (valproic acid capsules) and Depakote (divalproex sodium), with Epilim being widely used internationally, particularly in Europe and other regions. 1, 2, 3
Primary Brand Names
Depakene is the original brand name for valproic acid capsules, typically available as 250 mg soft gelatin capsules 1. This formulation contains pure valproic acid and has been used clinically for over 40 years 3.
Depakote is the brand name for divalproex sodium, which is a stable coordination compound of sodium valproate and valproic acid. This is one of the most frequently prescribed formulations in clinical practice 2.
Epilim is the brand name commonly used in the United Kingdom, Europe, and other international markets, representing sodium valproate 3.
Generic Availability
Generic valproic acid formulations are widely available and have been shown to be bioequivalent to brand-name products. A study demonstrated that generic Valproic Acid USP (manufactured by Solvay) was successfully substituted for Depakene without statistically significant changes in seizures or blood levels, while costing less than one-tenth the price of the brand-name product 4.
Clinical Context
The various brand names all refer to valproic acid or its salts, which function as broad-spectrum antiepileptic medications used for epilepsy, bipolar disorder, and migraine prophylaxis 5. Between 2017-2022, approximately 18.3% of all valproic acid prescriptions in the United States were issued to females of reproductive age, with the most common indication being migraine or headache syndromes (27.2%), followed by bipolar disorder (24.6%) and epilepsy (20.7%) 6.
Important caveat: Regardless of brand name, valproic acid should be avoided in women of childbearing potential when possible due to teratogenic risks 5, 7. When prescribing any valproic acid product, therapeutic drug monitoring is essential due to the narrow therapeutic window and significant interindividual pharmacokinetic variability 2, 8.